Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16867811 | 0.91 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16867688 | 0.90 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16868292 | 0.89 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16868298 | 0.88 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16868307 | 0.88 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16868283 | 0.87 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16868281 | 0.87 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16867689 | 0.85 | PDE2A (1.00) | PDE2A | |
| SCHEMBL19571234 | 0.85 | PDE2A (1.00) | PDE2A | |
| SCHEMBL18383474 | 0.84 | PDE2A (1.00) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087060-B1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3087060-B1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-13 | — | — | EP | disclosed |
| US-9815796-B2 | Pyrimidone carboxamide compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815796-B2 | Pyrimidone carboxamide compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-19 | — | — | US | disclosed |
| WO-2015096651-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE3A | PDE2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.